一、前言 近年來,隨著干細(xì)胞治療、免疫細(xì)胞治療和基因編輯等基礎(chǔ)理論、技術(shù)手段和臨床醫(yī)療探索研究的不斷發(fā)展,細(xì)胞治療產(chǎn)品為一些嚴(yán)重及難治性疾病提供了新的治療思路與方法。為規(guī)范和...
一、前言 近年來,隨著干細(xì)胞治療、免疫細(xì)胞治療和基因編輯等基礎(chǔ)理論、技術(shù)手段和臨床醫(yī)療探索研究的不斷發(fā)展,細(xì)胞治療產(chǎn)品為一些嚴(yán)重及難治性疾病提供了新的治療思路與方法。為規(guī)范和...
1.制定發(fā)布《細(xì)胞治療產(chǎn)品研究與評價技術(shù)指導(dǎo)原則》的背景是什么? 細(xì)胞治療技術(shù)是目前國際醫(yī)學(xué)前沿重點發(fā)展領(lǐng)域,它給一些人類疑難疾病的治療提供了新的希望。近年來,細(xì)胞治療領(lǐng)域不...
Emerging immuno-oncology player Tessa Therapeutics has raised $80 million in a financin...
WALTHAM, Mass.,Dec. 20, 2017/PRNewswire/ -- Juno Therapeutics (NASDAQ:JUNO) and Thermo ...
The blood-brain barrier disruption appears to be “a unique mechanism within this settin...
PHILADELPHIA,Nov. 17, 2017/PRNewswire/ -- WuXi AppTec (WuXi), a leading global pharmace...
Seattle Children’s has opened the first chimeric antigen receptor (CAR) T-cell immunoth...
The Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) in combinatio...
The FDA has granted Bluebird bb2121 a breakthrough therapy designation for previously t...
SHANGHAI, China and CUPERTINO, Calif.,November 7, 2017/GlobeNewswire/ —Cellular Biomedi...
November 6, 2017 – New York (N.Y.)– Cellectis (Alternext: ALCLS - Nasdaq: CLLS) a clini...
We have the following position open, if you are interested and feel it would be a good ...
SEOUL, South Korea,Nov. 6, 2017/PRNewswire/ --Eutilex Co. Ltd. today announced that it ...
Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-...
灣區(qū)最大的華人生物協(xié)會CABS國際合作部招募志愿者/委員會委員, Chinese American Bio/Pharmaceutical Society是灣區(qū)最大的華人生物協(xié)...